{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:34:04Z","timestamp":1793226844224,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009974","name":"Cardinal Tien Hospital","doi-asserted-by":"publisher","award":["CTH114A-2216"],"award-info":[{"award-number":["CTH114A-2216"]}],"id":[{"id":"10.13039\/501100009974","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009974","name":"Cardinal Tien Hospital","doi-asserted-by":"publisher","award":["CTH114A-NDMC-2228"],"award-info":[{"award-number":["CTH114A-NDMC-2228"]}],"id":[{"id":"10.13039\/501100009974","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009974","name":"Cardinal Tien Hospital","doi-asserted-by":"publisher","award":["CTH115A-NDMC-2218"],"award-info":[{"award-number":["CTH115A-NDMC-2218"]}],"id":[{"id":"10.13039\/501100009974","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009974","name":"Cardinal Tien Hospital","doi-asserted-by":"publisher","award":["CTH115A-FJU-2227"],"award-info":[{"award-number":["CTH115A-FJU-2227"]}],"id":[{"id":"10.13039\/501100009974","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaip.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:29:59Z","timestamp":1790206199000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ocular Safety of Dupilumab Compared With IL-5 Inhibitors in Asthma"],"prefix":"10.1016","author":[{"given":"Hsiao-Mei","family":"Tsao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hsien","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7426-0743","authenticated-orcid":false,"given":"Cheng-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Chien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.09.006_bib2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.09.006_bib3","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.006_bib4","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.006_bib5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.006_bib6","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.09.006_bib7","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.09.006_bib8","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.chest.2025.08.042","article-title":"Biologic management in severe asthma for adults: an American College of Chest Physicians Clinical Practice Guideline","volume":"169","author":"Oberle","year":"2026","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.09.006_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(25)00242-5","article-title":"2025 GINA report for asthma","author":"Venkatesan","year":"2025","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.jaip.2026.09.006_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2026.09.006_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/pharmaceutics15041031","article-title":"Association between dupilumab and conjunctivitis: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Lin","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jaip.2026.09.006_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-249019","article-title":"Dupilumab-induced ocular surface disease: a primer","volume":"15","author":"Reji","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2026.09.006_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40257-020-00577-1","article-title":"Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma","volume":"22","author":"Bansal","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2026.09.006_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12386","article-title":"Higher prevalence of dupilumab-induced ocular adverse events in atopic dermatitis compared to asthma: a daily practice analysis","volume":"14","author":"Schl\u00f6sser","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2026.09.006_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.15524","article-title":"Difference in the rate of ocular adverse events with dupilumab between asthma and atopic dermatitis patients","volume":"60","author":"Wang","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2026.09.006_bib16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.survophthal.2022.02.002","article-title":"Dupilumab-associated ocular manifestations: a review of clinical presentations and management","volume":"67","author":"Wu","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jaip.2026.09.006_bib17","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1513\/AnnalsATS.202306-566OC","article-title":"Comparative effectiveness of mepolizumab, benralizumab, and dupilumab among patients with difficult-to-control asthma: a multicenter retrospective propensity-matched analysis","volume":"21","author":"Kearney","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2026.09.006_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaip.2026.09.006_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2026.09.006_bib20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2026.09.006_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00067","article-title":"Using a federated network of real-world data to optimize clinical trials operations","volume":"2","author":"Topaloglu","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.jaip.2026.09.006_bib22","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaip.2026.09.006_bib23","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1056\/NEJMp2407586","article-title":"\u201cTarget trial emulation\u201d for observational studies - potential and pitfalls","volume":"391","author":"Hubbard","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.006_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.jaip.2026.09.006_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2026.09.006_bib26","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.09.006_bib27","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2026.09.006_bib28","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.006_bib29","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2026.09.006_bib30","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1111\/all.15326","article-title":"IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro","volume":"77","author":"Hansen","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.09.006_bib31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.exer.2013.08.013","article-title":"T helper cytokines in dry eye disease","volume":"117","author":"Pflugfelder","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jaip.2026.09.006_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.09.006_bib33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2026.09.006_bib34","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.006_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.jaip.2026.09.006_bib36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pds.1360","article-title":"Application of lag-time into exposure definitions to control for protopathic bias","volume":"16","author":"Tamim","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaip.2026.09.006_bib37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.1200","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics","volume":"15","author":"Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaip.2026.09.006_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1740774511420743","article-title":"Beyond the intention-to-treat in comparative effectiveness research","volume":"9","author":"Hern\u00e1n","year":"2012","journal-title":"Clin Trials"},{"key":"10.1016\/j.jaip.2026.09.006_bib39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","article-title":"A review of uses of health care utilization databases for epidemiologic research on therapeutics","volume":"58","author":"Schneeweiss","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaip.2026.09.006_bib40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/amiajnl-2013-002116","article-title":"ICD-10 codes used to identify adverse drug events in administrative data: a systematic review","volume":"21","author":"Hohl","year":"2014","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.jaip.2026.09.006_bib41","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1001\/jama.2011.822","article-title":"Surveillance bias in outcomes reporting","volume":"305","author":"Haut","year":"2011","journal-title":"JAMA"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826007816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826007816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:16:19Z","timestamp":1793225779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826007816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S2213219826007816"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.09.006","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Safety of Dupilumab Compared With IL-5 Inhibitors in Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}